Literature DB >> 7586724

Lymphocyte subsets and plasma IL-1 alpha, IL-2, and TNF-alpha concentrations in acute rheumatic fever and chronic rheumatic heart disease.

N Narin1, N Kütükçüler, R Ozyürek, A R Bakiler, A Parlar, M Arcasoy.   

Abstract

The distribution of CD3+, CD4+, CD8+, CD19+, CD16+, and CD25+ lymphocyte populations in peripheral blood as well as the plasma concentrations of interleukin-1 alpha (IL-1 alpha), and IL-2 and tumor necrosis factor alpha (TNF-alpha) were investigated in 25 children with acute rheumatic fever (ARF) at the time of admission and after 3 months and in 15 children with chronic rheumatic heart disease (CRHD) and in 15 children with streptoccocal pharyngitis (SP) in order to determine changes in lymphocyte subsets and cytokine concentrations occurring during different stages of the disease. The percentages and absolute counts of CD4+, CD16+, CD25+ cells, the ration of CD4/CD8 and plasma concentrations of IL-1 alpha and IL-2 in patients with ARF were significantly higher at admission than 3 months later. These levels were also significantly higher than in patients with CRHD, SP, or normal controls. Production of IL-2 in ARF and CRHD patients directly correlated with the percentages of CD4+ and CD25+ cells. According to our results, the evidences of increased cellular immune response in ARF are increased percentages CD4+ and CD25+ cells, CD4/CD8 ratio, and increased plasma concentrations of IL-1 alpha and IL-2. Furthermore, activation of cellular immune response was not present throughout all stages of rheumatic heart disease and also in SP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586724     DOI: 10.1006/clin.1995.1140

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

Review 1.  Understanding rheumatic fever.

Authors:  Pedro Ming Azevedo; Rosa Rodrigues Pereira; Luiza Guilherme
Journal:  Rheumatol Int       Date:  2011-09-28       Impact factor: 2.631

2.  Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty.

Authors:  Kumral Ergun Cagli; Dursun Aras; Serkan Topaloglu; Bilal Geyik; Selime Ayaz; Goksel Cagirci; Halil Lutfi Kisacik; Sule Korkmaz
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 3.  T cell subsets: an integral component in pathogenesis of rheumatic heart disease.

Authors:  Devinder Toor; Neha Sharma
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

4.  Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions.

Authors:  Luiza Guilherme; Patricia Cury; Lea M F Demarchi; Verônica Coelho; Lúcia Abel; Ana P Lopez; Sandra Emiko Oshiro; Selma Aliotti; Edécio Cunha-Neto; Pablo M A Pomerantzeff; Ana C Tanaka; Jorge Kalil
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

5.  Association of matrix metalloproteinase 3 and endogenous inhibitors with inflammatory markers in mitral valve disease and calcification.

Authors:  Sonia Aloui; Wiem Zidi; Sana Ouali; Imen Guizani; Sameh Hadj-Taieb; Mohamed Sami Mourali; Moncef Feki; Monia Allal-Elasmi
Journal:  Mol Biol Rep       Date:  2018-10-09       Impact factor: 2.316

6.  Genes, autoimmunity and pathogenesis of rheumatic heart disease.

Authors:  L Guilherme; K F Köhler; E Postol; J Kalil
Journal:  Ann Pediatr Cardiol       Date:  2011-01

7.  An investigation of tenascin-C levels in rheumatic mitral stenosis and their response to percutaneous mitral balloon valvuloplasty.

Authors:  Ahmet Celik; Ozgur Gunebakmaz; Oguzhan Baran; Orhan Dogdu; Deniz Elcik; Mehmet Ali Kobat; Mehmet Balin; Kenan Erdem; Suleyman Aydin; Ibrahim Ozdogru; Ramazan Topsakal
Journal:  Med Princ Pract       Date:  2012-08-08       Impact factor: 1.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.